Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes

Drexler, S.; Cai, C.; Hartmann, A.L.; Moch, D.; Gaitantzi, H.; Ney, T.; ... ; Breitkopf-Heinlein, K. (2023)

Article / Letter to editor

Bone morphogenetic protein (BMP)-9, a member of the TGF beta-family of cytokines, is believed to be mainly produced in the liver. The serum levels of BMP-9 were reported to be reduced in newly diagnosed diabetic patients and BMP-9 overexpression ameliorated steatosis in the high fat diet-induced obesity mouse model. Furthermore, injection of BMP-9 in mice enhanced expression of fibroblast growth factor (FGF)21. However, whether BMP-9 also regulates the expression of the related FGF19 is not clear. Because both FGF21 and 19 were described to protect the liver from steatosis, we have further investigated the role of BMP-9 in this context.We first analyzed BMP-9 levels in the serum of streptozotocin (STZ)-induced diabetic rats (a model of type I diabetes) and confirmed that BMP-9 serum levels decrease during diabetes. Microarray analyses of RNA samples from hepatic and intestinal tissue from BMP-9 KO-and wild-type mice (C57/Bl6 background) pointed to basal expression of BMP-9 in both organs and revealed a down-regulation of hepatic Fgf21 and intestinal Fgf19 in the KO mice. Next, we analyzed BMP-9 levels in a cohort of obese patients with or without diabetes. Serum BMP-9 levels did not correlate with diabetes, but hepatic BMP-9 mRNA expression negatively correlated with steatosis in those patients that did not yet develop diabetes. Likewise, hepatic BMP-9 expression also negatively correlated with serum LPS levels. In situ hybridization analyses confirmed intestinal BMP-9 expression. Intestinal (but not hepatic) BMP-9 mRNA levels were decreased with diabetes and positively correlated with intestinal E-Cadherin expression. In vitro studies using organoids demonstrated that BMP-9 directly induces FGF19 in gut but not hepatocyte organoids, whereas no evidence of a direct induction of hepatic FGF21 by BMP-9 was found. Consistent with the in vitro data, a correlation between intestinal BMP-9 and FGF19 mRNA expression was seen in the patients' samples.In summary, our data confirm that BMP-9 is involved in diabetes development in humans and in the control of the FGF-axis. More importantly, our data imply that not only hepatic but also intestinal BMP-9 associates with diabetes and steatosis development and controls FGF19 expression. The data support the conclusion that increased levels of BMP-9 would most likely be beneficial under pre-steatotic conditions, making supplemen-tation of BMP-9 an interesting new approach for future therapies aiming at prevention of the development of a metabolic syndrome and liver steatosis.

• Diabetes
• BMP-9
• GDF2
• Obesity
• Liver steatosis
• LPS

• All authors: Drexler, S.; Cai, C.; Hartmann, A.L.; Moch, D.; Gaitantzi, H.; Ney, T.; Kraemer, M.; Chu, Y.; Zheng, Y.W.; Rahbari, M.; Treffs, A.; Reiser, A.; Lenoir, B.; Valous, N.A.; Jager, D.; Birgin, E.; Sawant, T.A.; Li, Q.; Xu, K.S.; Dong, L.Y.; Otto, M.; Itzel, T.; Teufel, A.; Gretz, N.; Hawinkels, L.J.A.C.; Sanchez, A.; Herrera, B.; Schubert, R.; Moshage, H.; Reissfelder, C.; Ebert, M.P.A.; Rahbari, N.N.; Breitkopf-Heinlein, K.
• Date: 2023-04-24
• Journal: Molecular and Cellular Endocrinology
• Volume: 570
• DOI: doi:10.1016/j.mce.2023.111934